Results 191 to 200 of about 1,756,222 (351)

Cost‐effectiveness of low dose colchicine prophylaxis when starting allopurinol using the “start‐low go‐slow” approach for gout: evidence from a non‐inferiority randomised double‐blind placebo‐controlled trial.

open access: yesArthritis Care &Research, Accepted Article.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko   +4 more
wiley   +1 more source

Identifying High‐Impact Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus‐Based Approach

open access: yesArthritis Care &Research, Accepted Article.
Objective We conducted formative research aimed at identifying solutions that address inequitable health outcomes in lupus due to adverse social determinants of health. Methods We conducted a search for keywords which provided insights into potential solutions and initiatives underway. An advisory panel of lupus experts iteratively reviewed the list of
Joy Buie   +11 more
wiley   +1 more source

A continuing medical education course for physicians and mid-level practitioners

open access: bronze, 1979
B D Burr   +3 more
openalex   +1 more source

Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis

open access: yesArthritis Care &Research, Accepted Article.
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy